MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT07505745
StatusRecruiting
PhasePhase 2
SponsorHudson Biotech
Enrollment120 participants
DesignInterventional, Randomized, Parallel, Masking: Quadruple
ConditionsPrediabetes; Insulin Resistance; Overweight/Obesity
InterventionsMOTS-c (MDP); Placebo; Route Subcutaneous injection; Regimen
StartFeb 2, 2026
Primary completionFeb 14, 2027
Study completionMay 17, 2028
Results postedNot yet
Registry last updatedApr 1, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity.

Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index)12 Weeks
Incidence of treatment-emergent adverse events (TEAEs)16 weeks

4 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

More from Hudson Biotech

Research area: Longevity and mitochondrial. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.

Share thisFacebookXEmail